| Literature DB >> 29178011 |
Raffaele Falsaperla1, Maria Stella Vari2, Irene Toldo3, Alessandra Murgia3, Stefano Sartori3, Marilena Vecchi3, Agnese Suppiej3, Alberto Burlina4, Mario Mastrangelo5, Vincenzo Leuzzi5, Valentina Marchiani6, Paola De Liso5, Giuseppe Capovilla7, Pasquale Striano2, Giovanna Vitaliti8.
Abstract
The aim of our study was to describe the clinical, electroencephalogram, molecular findings and the diagnostic and therapeutic flow-chart of children with pyridoxine-dependent epilepsies (PDEs). We performed a retrospective observational study on children with PDEs, diagnosed and followed-up in Italian Pediatric Departments. In each centre, the authors collected data from a cohort of children admitted for intractable seizures, responsive to pyridoxine administration and resistant to other anticonvulsant therapies. Data were retrospectively analysed from January 2016 to January 2017. Sixteen patients (13 males, and 3 females) were included. We found that 93.75% of patients underwent conventional anticonvulsant therapy before starting pyridoxine administration and 62.5% had ex-juvantibus diagnosis, as specific serum diagnostic tests had been performed in only 37.5% of patients by alpha-AASA and pipecolic acid blood and urine dosage. The most common type of seizure was generalized tonic-clonic in 7 patients and the most common EEG pattern was characterized by a "burst suppression" pattern. Before pyridoxine administration, other anticonvulsant drugs were used in 93.75% of patients, with consequent onset of drug-resistance. Phenobarbital was the most frequently used drug as first-line treatment. The importance of our study relies on the need of a deeper knowledge of PDEs in terms of early diagnosis, avoiding incorrect treatment and related adverse events, clinical and EEG pathognomonic features, and genetic aspects of the disease.Entities:
Keywords: Cohort; Dependent epilepsies; Diagnosis; Observational study; Pediatric age; Pyridoxine; Treatment
Mesh:
Substances:
Year: 2017 PMID: 29178011 DOI: 10.1007/s11011-017-0150-x
Source DB: PubMed Journal: Metab Brain Dis ISSN: 0885-7490 Impact factor: 3.584